A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

E. Van Cutsem, C. Pozzo, H. Starkhammar, L. Dirix, E. Terzoli, F. Cognetti, Y. Humblet, C. Garufi, L. Filez, G. Gruia, C. Cote, C. Barone

Research output: Contribution to journalArticle

Abstract

Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5- fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC). Patients and methods: Patients with histologically proven metastatic colorectal cancer, and at least one bidimensionally measurable lesion, aged 18-70, with performance status ≤ 2, normal baseline biological values and no prior chemotherapy (or only adjuvant chemotherapy completed ≥ 6 months before study entry) were selected. Treatment was irinotecan 350 mg/m2, i.v., day 1, alternating with leucovorin 20 mg/m2 i.v. and 5-FU 425 mg/m2, i.v. daily for five consecutive days, day 22-26 (Mayo Clinic regimen). One alternating cycle was to be performed every six weeks. Patients were evaluated for efficacy every alternating cycle. Treatment was administered until five alternating cycles, disease progression, unacceptable toxicity or patient refusal. Results: Thirty-three patients (28 chemotherapy-naive and five with prior adjuvant treatment completed > 1 year prior to accrual) were enrolled. The objective response rate (RR) was 30% (95% CI: 16-49; 10 patients/33; nine partial response and one complete response). All responses were reviewed by an independent external review committee. An additional 49% of patients had stable disease. The median survival was 16 months, the one year survival amounted to 58% and the median progression free survival was 7.2 months. Relative dose intensity was nearly 90% for both drugs. Grade 3-4 diarrhea and neutropenia were the most frequent severe toxic events, seen in 24% and 64% of patients, respectively. Conclusions: The alternating schedule of CPT-11 350 mg/m2 with five days bolus of 5-FU and low dose LV is an active and feasible regimen as front-line therapy for metastatic CRC. It is well tolerated, without evidence of overlapping toxicity. The response rate appears promising with regard to that expected with either single agent. This regimen warrants further assessment in randomized trials.

Original languageEnglish
Pages (from-to)1199-1204
Number of pages6
JournalAnnals of Oncology
Volume9
Issue number11
DOIs
Publication statusPublished - Nov 1998

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
Drug Therapy
Appointments and Schedules
Survival
Poisons
Advisory Committees
Therapeutics
Adjuvant Chemotherapy
Neutropenia

Keywords

  • Alternating combination
  • Bolus fluorouracil
  • CPT-11
  • First-line chemotherapy
  • Irinotecan
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. / Van Cutsem, E.; Pozzo, C.; Starkhammar, H.; Dirix, L.; Terzoli, E.; Cognetti, F.; Humblet, Y.; Garufi, C.; Filez, L.; Gruia, G.; Cote, C.; Barone, C.

In: Annals of Oncology, Vol. 9, No. 11, 11.1998, p. 1199-1204.

Research output: Contribution to journalArticle

Van Cutsem, E, Pozzo, C, Starkhammar, H, Dirix, L, Terzoli, E, Cognetti, F, Humblet, Y, Garufi, C, Filez, L, Gruia, G, Cote, C & Barone, C 1998, 'A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer', Annals of Oncology, vol. 9, no. 11, pp. 1199-1204. https://doi.org/10.1023/A:1008478405634
Van Cutsem, E. ; Pozzo, C. ; Starkhammar, H. ; Dirix, L. ; Terzoli, E. ; Cognetti, F. ; Humblet, Y. ; Garufi, C. ; Filez, L. ; Gruia, G. ; Cote, C. ; Barone, C. / A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. In: Annals of Oncology. 1998 ; Vol. 9, No. 11. pp. 1199-1204.
@article{b71d5d6667e4407f8919b69b5205c2d4,
title = "A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer",
abstract = "Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5- fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC). Patients and methods: Patients with histologically proven metastatic colorectal cancer, and at least one bidimensionally measurable lesion, aged 18-70, with performance status ≤ 2, normal baseline biological values and no prior chemotherapy (or only adjuvant chemotherapy completed ≥ 6 months before study entry) were selected. Treatment was irinotecan 350 mg/m2, i.v., day 1, alternating with leucovorin 20 mg/m2 i.v. and 5-FU 425 mg/m2, i.v. daily for five consecutive days, day 22-26 (Mayo Clinic regimen). One alternating cycle was to be performed every six weeks. Patients were evaluated for efficacy every alternating cycle. Treatment was administered until five alternating cycles, disease progression, unacceptable toxicity or patient refusal. Results: Thirty-three patients (28 chemotherapy-naive and five with prior adjuvant treatment completed > 1 year prior to accrual) were enrolled. The objective response rate (RR) was 30{\%} (95{\%} CI: 16-49; 10 patients/33; nine partial response and one complete response). All responses were reviewed by an independent external review committee. An additional 49{\%} of patients had stable disease. The median survival was 16 months, the one year survival amounted to 58{\%} and the median progression free survival was 7.2 months. Relative dose intensity was nearly 90{\%} for both drugs. Grade 3-4 diarrhea and neutropenia were the most frequent severe toxic events, seen in 24{\%} and 64{\%} of patients, respectively. Conclusions: The alternating schedule of CPT-11 350 mg/m2 with five days bolus of 5-FU and low dose LV is an active and feasible regimen as front-line therapy for metastatic CRC. It is well tolerated, without evidence of overlapping toxicity. The response rate appears promising with regard to that expected with either single agent. This regimen warrants further assessment in randomized trials.",
keywords = "Alternating combination, Bolus fluorouracil, CPT-11, First-line chemotherapy, Irinotecan, Metastatic colorectal cancer",
author = "{Van Cutsem}, E. and C. Pozzo and H. Starkhammar and L. Dirix and E. Terzoli and F. Cognetti and Y. Humblet and C. Garufi and L. Filez and G. Gruia and C. Cote and C. Barone",
year = "1998",
month = "11",
doi = "10.1023/A:1008478405634",
language = "English",
volume = "9",
pages = "1199--1204",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - A phase II study of irinotecan alternated with five days bolus of 5- fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer

AU - Van Cutsem, E.

AU - Pozzo, C.

AU - Starkhammar, H.

AU - Dirix, L.

AU - Terzoli, E.

AU - Cognetti, F.

AU - Humblet, Y.

AU - Garufi, C.

AU - Filez, L.

AU - Gruia, G.

AU - Cote, C.

AU - Barone, C.

PY - 1998/11

Y1 - 1998/11

N2 - Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5- fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC). Patients and methods: Patients with histologically proven metastatic colorectal cancer, and at least one bidimensionally measurable lesion, aged 18-70, with performance status ≤ 2, normal baseline biological values and no prior chemotherapy (or only adjuvant chemotherapy completed ≥ 6 months before study entry) were selected. Treatment was irinotecan 350 mg/m2, i.v., day 1, alternating with leucovorin 20 mg/m2 i.v. and 5-FU 425 mg/m2, i.v. daily for five consecutive days, day 22-26 (Mayo Clinic regimen). One alternating cycle was to be performed every six weeks. Patients were evaluated for efficacy every alternating cycle. Treatment was administered until five alternating cycles, disease progression, unacceptable toxicity or patient refusal. Results: Thirty-three patients (28 chemotherapy-naive and five with prior adjuvant treatment completed > 1 year prior to accrual) were enrolled. The objective response rate (RR) was 30% (95% CI: 16-49; 10 patients/33; nine partial response and one complete response). All responses were reviewed by an independent external review committee. An additional 49% of patients had stable disease. The median survival was 16 months, the one year survival amounted to 58% and the median progression free survival was 7.2 months. Relative dose intensity was nearly 90% for both drugs. Grade 3-4 diarrhea and neutropenia were the most frequent severe toxic events, seen in 24% and 64% of patients, respectively. Conclusions: The alternating schedule of CPT-11 350 mg/m2 with five days bolus of 5-FU and low dose LV is an active and feasible regimen as front-line therapy for metastatic CRC. It is well tolerated, without evidence of overlapping toxicity. The response rate appears promising with regard to that expected with either single agent. This regimen warrants further assessment in randomized trials.

AB - Purpose: This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5- fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC). Patients and methods: Patients with histologically proven metastatic colorectal cancer, and at least one bidimensionally measurable lesion, aged 18-70, with performance status ≤ 2, normal baseline biological values and no prior chemotherapy (or only adjuvant chemotherapy completed ≥ 6 months before study entry) were selected. Treatment was irinotecan 350 mg/m2, i.v., day 1, alternating with leucovorin 20 mg/m2 i.v. and 5-FU 425 mg/m2, i.v. daily for five consecutive days, day 22-26 (Mayo Clinic regimen). One alternating cycle was to be performed every six weeks. Patients were evaluated for efficacy every alternating cycle. Treatment was administered until five alternating cycles, disease progression, unacceptable toxicity or patient refusal. Results: Thirty-three patients (28 chemotherapy-naive and five with prior adjuvant treatment completed > 1 year prior to accrual) were enrolled. The objective response rate (RR) was 30% (95% CI: 16-49; 10 patients/33; nine partial response and one complete response). All responses were reviewed by an independent external review committee. An additional 49% of patients had stable disease. The median survival was 16 months, the one year survival amounted to 58% and the median progression free survival was 7.2 months. Relative dose intensity was nearly 90% for both drugs. Grade 3-4 diarrhea and neutropenia were the most frequent severe toxic events, seen in 24% and 64% of patients, respectively. Conclusions: The alternating schedule of CPT-11 350 mg/m2 with five days bolus of 5-FU and low dose LV is an active and feasible regimen as front-line therapy for metastatic CRC. It is well tolerated, without evidence of overlapping toxicity. The response rate appears promising with regard to that expected with either single agent. This regimen warrants further assessment in randomized trials.

KW - Alternating combination

KW - Bolus fluorouracil

KW - CPT-11

KW - First-line chemotherapy

KW - Irinotecan

KW - Metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=7844220589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844220589&partnerID=8YFLogxK

U2 - 10.1023/A:1008478405634

DO - 10.1023/A:1008478405634

M3 - Article

C2 - 9862050

AN - SCOPUS:7844220589

VL - 9

SP - 1199

EP - 1204

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -